Abstract: An insulating container comprises a container body and a container cover connected to the container body. The container both and the container cover each comprises a frame and a plate arranged on the frame. The plate comprises, from inside out, an external high strength sheet, an extruded polystyrene sheet, phase-change insulating sheets made of phase-change material, and an internal sheet. A phase-change process of the phase-change insulating sheets cooperates with a refrigeration system of the transportation device to precisely control the temperature of the insulating container and a refrigerator truck to be near a phase-change temperature. In the present disclosure, the phase-change insulating sheets made of the phase-change material remain to be in a solid state before or after occurrence of a phase change, so that the structure of the insulating container does not change with the phase change and a leakage problem of the phase-change material does not exist.

Abstract: This disclosure relates to the compounds of formula (I) [INSERT FORMULA], in which A and R1-R12 are defined in the Specification. The compounds of formula (I) have therapeutic effects, such as treating cancers.

Abstract: The present disclosure is directed to a vibration isolation pallet, comprising a support platform and a vibration isolation component arranged on top. The vibration isolation component further comprises a top and a bottom supporting plate with a plurality of spherical dampers and support columns strategically disposed in between. The edges of the top and bottom supporting plates are reinforced together with rubber damping pieces at various locations. The vibration isolation component can be detached from the support platform and functions independently. The pallet as whole can be serviced and maintained for repeated use.

Abstract: Disclosed are novel compounds of Formula I that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

Abstract: Disclosed are cyclic-di-nucleotide cGAMP analogs, methods of synthesizing the compounds, pharmaceutical compositions comprising the compounds thereof, and use of compounds and compositions in medical therapy.

Abstract: A thermal container insulated with phase change material comprising a plurality of panels to form a body with a plurality of sides, a bottom and a lid, wherein each panel further comprises: a lining board, a phase change cold storage board, an insulation board; and a skin board. The phase change cold storage board further comprises an array of openings filled with solid-solid phase change material. The thermal container can maximize its storage capacity without compromising any volume for ice. It can maintain an accurate temperature range suitable for transportation. The container is reinforced at various locations to improve stability and structural integrity.

Abstract: The present disclosure is for a vibration isolation pallet, comprising a support platform, a vibration isolation component arranged on top. The vibration isolation component comprises a top and a bottom supporting plate with a plurality of spherical dampers strategically disposed in between. The supporting plates are reinforced with rubber damping pieces around its edges. The vibration isolation component can be independently installed onto various transportation means such as a pushcart or a vehicle. The pallet as whole can be serviced and maintained for repeated use.

Abstract: Described herein are methods of using Substance P, mast cell degranulation inhibitors, or combinations thereof to delay the onset of, to reverse, or to reduce the risk of acquiring complications associated with diabetes. Also provided herein are methods for accelerating wound healing in diabetic subjects using Substance P, mast cell degranulation inhibitors, or combinations thereof.

Abstract: The invention features all-trans retinoic acid (ATRA)-related compounds capable of associating with Pin1 and methods of treating a proliferative disorder characterized by elevated Pin1 marker levels, Pin1 degradation, and/or reduced Pin1 Ser71 phosphorylation in a subject by administering an ATRA-related compound. The invention also features methods of treating proliferative disorders, autoimmune diseases, and addiction conditions (e.g., diseases, disorders, and conditions characterized by elevated Pin1 marker levels) by administering an ATRA-related compound in combination with another therapeutic compound.

Abstract: Cyclic-GMP-AMP (cGAMP), including 2?,3?-cGAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies and diagnostics.

Abstract: The invention relates to compounds of structural formula (I) and structural formula (VI): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein R, R1, R2, Z, L, and n are defined herein. Those compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

Abstract: Disclosed is a compound represented by the Structural Formula (I): Y is a covalent bond, a phenylene group or a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C?Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or —C(R7R8)—. R1 and R2 are independently an aryl group or a substituted aryl group, R3 and R4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R5-R6 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R7 and R8 are each independently —H, an aliphatic or substituted aliphatic group, or R7 is —H and R8 is a substituted or unsubstituted aryl group, or, R7 and R8, taken together, are a C2-C6 substituted or unsubstituted alkylene group. Z is ?O or ?S.

Abstract: Cyclic-GMP-AMP synthase (cGAS) and cyclic-GMP-AMP (cGAMP), including 2?3-cGAMP, 2?2-cGAMP, 3?2?-cGAMP and 3?3?-GAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies and diagnostics.

Abstract: The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, and prodrug thereof, wherein Ra, Rb, and R2 are defined herein. These compounds inhibit tubulin polymerization and/or target vasculature and are useful for treating proliferative disorders, such as cancer.

Abstract: Disclosed are compounds of formulae (I), (III), (IV), (VII), (X), (XI), (XII), (XIII) and (XIV), wherein the variables are as defined in the claims, and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier.

Abstract: The invention relates to compounds of structural formula (I) and structural formula (VI): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein R, R1, R2, Z, L, and n are defined herein. Those compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.